Sign In
Buy QURE
$46.06
-0.360 (-0.776%)
At Close: Aug 10, 2026
QURE Stock: Over 5% Increase Pre-Market Explanation
07:55am, Monday, 26'th Apr 2021
The stock price of Uniqure NV (NASDAQ: QURE) has increased by over 5% pre-market. This is why it happened.
uniQure Announces FDA Removes Clinical Hold on Hemophilia B Gene Therapy Program
07:05am, Monday, 26'th Apr 2021
LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with sev
Publication in Science Translational Medicine shows local striatal delivery of microRNA-gene therapy results in widespread brain huntingtin protein lowering in Huntington's disease minipigs Publicatio
uniQure: A High-Risk, High-Reward Investment Opportunity
09:32pm, Wednesday, 07'th Apr 2021
uniQure has submitted data to the FDA that suggest that etranacogene dezaparvovec (AMT-061) is highly unlikely to be the cause of liver cancer in a patient in the pivotal trial. FTC review of the tran
~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~
uniQure to Participate in Multiple Upcoming Industry Conferences in April
07:05am, Thursday, 01'st Apr 2021
LEXINGTON, Mass. and AMSTERDAM, April 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs
uniQure Stock Is Higher After Investigators Conclude Its Gene Therapy Treatment Was Unlikely to Have Caused a Patient's Cancer
03:05pm, Monday, 29'th Mar 2021
Regulators froze uniQure's trial of its gene therapy for hemophilia in December when one of the 54 treated patients developed liver cancer.
Uniqure Stock Pops After Gene Therapy Acquitted In Cancer Diagnosis
10:37am, Monday, 29'th Mar 2021
Biotech company Uniqure said Monday an investigation shows its hemophilia B gene therapy likely wasn't the culprit in a patient's cancer diagnosis. QURE stock popped on the news report.
Uniqure's Hemophilia B Gene Therapy Unlikely To Be Cause Of Liver Cancer Reported In One Patient
09:26am, Monday, 29'th Mar 2021
Uniqure NV (NASDAQ: QURE) has reported results of a comprehensive investigation into the case of hepatocellular carcinoma (HCC) diagnosed in one patient in the HOPE-B pivotal trial of etranacogene
uniQure Announces Findings from Reported Case of Hepatocellular Carcinoma (HCC) in Hemophilia B Gene Therapy Program
07:05am, Monday, 29'th Mar 2021
~ Independent investigation shows that etranacogene dezaparvovec is highly unlikely to be the cause of HCC in HOPE-B pivotal trial ~
Rocket Pharmaceuticals Primed for Takeoff
06:19pm, Monday, 15'th Mar 2021
With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey.
UniQure (QURE) Reports Q4 Loss, Lags Revenue Estimates
09:07am, Monday, 01'st Mar 2021
uniQure (QURE) delivered earnings and revenue surprises of 98.72% and -59.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
uniQure Announces 2020 Financial Results and Highlights Recent Company Progress
07:05am, Monday, 01'st Mar 2021
~ Six patient procedures now completed in Phase I/II for Huntington's disease, including two procedures conducted in February 2021, with full enrollment of first cohort expected mid-2021 ~
uniQure to Participate in Multiple Upcoming Industry Conferences in March
07:05am, Friday, 26'th Feb 2021
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with seve
UniQure (QURE) to Report Q4 Results: Wall Street Expects Earnings Growth
01:39pm, Monday, 22'nd Feb 2021
UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
